Company Website:
http://www.glancylaw.com/
LOS ANGELES -- (Business Wire)
Glancy
Binkow & Goldberg LLP reminds investors of Sanofi
(the “Company”) (NYSE:SNY) that purchasers of Sanofi securities between
February 7, 2013 and December 3, 2014, inclusive (the “Class Period”),
have until February 2, 2015, to file a motion to be appointed as lead
plaintiff in the shareholder lawsuit filed in the United States District
Court for the Southern District of New York.
Sanofi is engaged in the discovery, development and distribution of
therapeutic solutions, including consumer health care products,
pharmaceuticals and vaccines used by veterinarians and generic
medicines. The Complaint alleges that defendants misrepresented or
failed to disclose that the Company was making improper payments to
healthcare professionals in connection with the sale of pharmaceutical
products, in violation of federal law, and that Sanofi’s internal
controls over financial reporting were inadequate.
On October 6, 2014, Sanofi issued a statement announcing that the
Company was investigating allegations related to improper payments to
healthcare workers in connection with the sale of pharmaceutical
products that may have occurred between 2007 and 2012 in certain parts
of the Middle East and East Africa. Then, on October 29, 2014, Sanofi
announced that its Board of Directors had decided to terminate
Christopher A. Viehbacher from his position as Chief Executive Officer
of Sanofi.
On December 3, 2014, media outlets reported that a former Sanofi
employee filed a whistleblower lawsuit in New Jersey against the
Company, alleging that the recently ousted CEO and other executives at
the Company participated in a scheme “over the course of many years” to
funnel tens of millions of dollars in kickbacks and other incentives to
get the Company’s diabetes drugs prescribed and sold.
If you are a member of the Class described above, you may move the Court
no later than February 2, 2015, to serve as lead plaintiff; however, you
must meet certain legal requirements. To be a member of the Class you
need not take any action at this time; you may retain counsel of your
choice or take no action and remain an absent member of the Class. If
wish to learn
more about this action, or if you have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley
Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park
East, Suite 2100, Los Angeles, California 90067, at 310-201-9150, by
e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts:
Glancy Binkow & Goldberg LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
Source: Glancy Binkow & Goldberg LLP
© 2024 Canjex Publishing Ltd. All rights reserved.